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A b s t r a c t
Introduction: The objective of this study was to evaluate the efficacy of surgery
plus adjuvant radiotherapy in 98 uterine sarcoma (US) patients and to analyse
reasons for treatment failure and the prognostic factors in those patients.
Material and methods: Between 1980 and 2000, 98 patients with uterine sarcoma
were treated with surgery followed by postoperative radiotherapy. This group
consisted of 70 patients with leiomyosarcoma (LMS) and 28 patients with
endometrial stromal sarcoma (ESS).
Results: Five-year survival rate with no evidence of disease (NED) was 49% for 98
US patients. In the ESS subgroup, 5 year survival rate with NED was 75% and in
the LMS subgroup only 38.6%. Analysis of the outcomes based on stage
of disease revealed that in the early stage group (FIGO stages I and II) 60.8%
of US patients survived for 5 years with NED, whereas in locally advanced stages
(stages III, IVA) only 12.5% survived for 5 years with NED. In the LMS subgroup
the dominant reason for treatment failure was distant metastases, while in
the ESS subgroup, there were locoregional recurrences.
Conclusions: Combined surgery plus radiotherapy was a relatively effective
therapy only in the treatment of early stage US (stages I and II). Independent
prognostic factors in this group of patients were stage and microscopic type
of sarcoma. The basic reason for failure of combined treatment in the group
of LMS patients was the spread of malignancy, while in ESS patients it was
regional recurrence.
Key words: uterine sarcomas, treatment, surgery, radiotherapy, prognostic factors.
Introduction
Uterine sarcomas (US) are rare tumours, making up 2 to 7% of all uterine
malignancies [1, 2]. The choice of treatment in patients with uterine sarcoma
is total abdominal hysterectomy (TAH) or bilateral salpingo-oophorectomy
(BSO) with or without lymph node sampling [1-3]. The role of postoperative
radiotherapy is the subject of controversy, and few clinical trials have been
carried out as yet to conclusively define its role [1, 3, 4]. The majority
of reports point out that postoperative radiotherapy improves curability but
does not positively affect survival [4] and some authors say that it not only
reduces the number of failures in treatment but also improves overall
survival rates [1, 5]. Anthracycline-based chemotherapy plays rather
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Numerous controversies are raised by the issue
of prognostic factors in US patients and the
literature mentions many of them, including US
microscopic type, degree of differentiation, mitotic
index, p53 and Ki67 protein expression, patient age,
hormonal status, tumour size and location, stage
of disease, depth of endometrial infiltration, regional
lymph node status, and other factors [3, 5, 10]. In
multivariate analyses presented by various authors
only some of them repeatedly show independent
prognostic effects. The objective of this retrospective
study is to assess the efficacy of combined
treatment of patients with US (surgery plus
radiotherapy) and to analyze the prognostic factors
in this group of patients.
Material and methods
Between 1980 and 2000, 128 patients with
uterine sarcomas were treated at the Centre
of Oncology, Maria Sklodowska-Curie Memorial
Institute, Krakow Branch. In this analysis group,
11 (8.6%) patients had advanced US with numerous
distant metastases, qualifying solely for palliative
treatment. In 2 (1.5%) patients, surgery alone was
performed, as both patients died shortly after
the operation due to non-gynaecological causes.
In 17 (13.3%) patients, postoperative chemotherapy
with CYVADIC (cyclophosphamide, vincristine,
doxorubicin and dacarbazine) was applied. The
subject of further analysis is a group of 98 (76.6%)
patients managed with the combined treatment
of surgery followed by radiotherapy.
In all patients the classical laparotomy and
hysterectomy with bilateral adnexectomy (TAH and
BSO) was performed. The FIGO classification for
cancer staging was used to assess tumour
advancements [11]. Adjuvant radiotherapy involving
brachy- and teletherapy was started 3-4 weeks after
surgical treatment. For intravaginal brachytherapy
(Selectron LDR/MDR) applicators employing
the after-loading technique were used (until 1990,
radium, and since 1991, caesium). The latter
involved 2 applications, a 20 Gy surface dose each,
with 7-day interval periods. For radium applicators,
there was a single application with a surface dose
of 50 Gy. The postoperative teletherapy was
performed with Cobalt 60 gamma photons 
(32 patients) or X-photons with 6-10 MeV energy
obtained from linear accelerators (66 patients).
Four-field technique was used with anterior,
posterior and two lateral beams (“box technique”).
The total dose was 50.4 Gy given in 24 fractions
over 5 weeks. Postoperative radiotherapy was very
well tolerated. Ninety six (98%) patients completed
their scheduled treatment. In 2 (2%) patients
the treatment was discontinued due to deterioration
of performance status and intensification
of coexisting diseases. Late complications (stages
3 and 4 according to the Chassagne et al.
classification), were found in 2 (2%) patients in
the form of rectovaginal fistula in one patient and
intestinal stenosis requiring surgical treatment in
the other. The sequelae appeared at months 18
and 23 post-treatment and both patients survived
without evidence of disease.
Survival, calculated from the date of surgery, was
a median time period of 98 months (66-194 months).
Total recurrence-free survival rate was measured by
the Kaplan Meier method. The log-rank test by Peto 
et al. was used for assessment of significance. Cox’s
proportional hazard model analysis was applied to
assess the influence of selected factors on survival data.
Results
The patients’ age ranged between 36 and
76 years. The medium age was 61 years. From
among 70 LMS patients, 31 (44.3%) were aged
under 60 years, whereas from among 28 ESS
patients, as many as 21 (75%) patients were aged
under 60 years. This difference was statistically
significant (log-rank test, p < 0.02). The mean age
of LMS patients (63 years) was significantly higher
than that for ESS patients (52 years).
Stage I US was diagnosed in 58 (59.2%) patients,
stage II in 16 (16.3%) and stages III or IVA in
24 (24.5%) patients. In 5 patients (4 stage III and
1 stage IVA), metastatic regional lymph nodes were
found. No statistically significant differences in grade
were observed between the group of patients with
LMS and those with ESS.
Leiomyosarcoma (LMS) was found in 70 (71.4%),
and endometrial stromal sarcoma (ESS) in
28 (28.6%) patients. From among 28 ESS patients,
low-grade ESS was diagnosed in 25 and high-grade
ESS in only 3 patients. No other US microscopic
types (e.g. rhabdo-, myo-, lipo-, or fibrosarcoma) were
found. Although many authors consider mixed
müllerian sarcomas (carcinosarcomas) histologically
as belonging to sarcomas [12, 13], those neoplasms
were not included in the US group in accordance
with the present WHO standpoint [14-16].
Table I presents population, clinical and
microscopic characteristics of these patients. Forty
nine percent of patients survived five years with no
evidence of disease (5-year NED). The treatment
results, depending on clinical and histological
parameters, are presented in Tables II, III.
Uni- and multivariate analyses did not show
statistical significance for such parameters as: age,
differentiation, or depth of myometrial infiltration.
The factors providing statistically significant
differences in patients’ survival were: LMS
histological type and FIGO stage III and IVA
advancement.
As seen in Table III, 22 (52.4%) patients from
among 42 stage I LMS patients and 4 (40%) patients
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from among 10 stage II LMS patients survived
5 years with no evidence of disease. Only one
patient with stage III LMS survived for 5 years with
no evidence of disease.
In the study group, out of 16 stage I ESS
patients, 5-year NED survival was observed in
15 (93.8%) women, and out of 6 stage II patients,
in 4 (66.7%). From among 3 patients with high-grade
ESS (G2, G3), 1 stage II patient survived for 5 years
with no evidence of disease, while the other two,
with stage III, died due to sarcoma spread to
the lungs. One patient had locoregional recurrence
after 4 years and is still alive with stable disease.
She was not analyzed as a 5-year NED survivor.
At the time of completion of the study
(September 2006), 49 patients had died, including
two who died due to concurrent diseases (cerebral
haemorrhage, myocardial infarct). The medium time
Uterine sarcomas – treatment and prognostic factors
Population, microscopic
Microscopic type of sarcoma Total
and clinical features LMS ESS No. of pts. %
No. of pts. % No. of pts. %
Age:
– under 60 31 44.3 21 75.0 52 53.1
– 60 and over 39 55.7 7 25.0 46 46.9
Clinical stage of disease:
– I 42 60.0 16 57.2 58 59.2
– II 10 14.3 6 21.4 16 16.3
– III 11 15.7 3 10.7 14 14.3
– IVA 7 10.0 3 10.7 10 10.2
Grade:
– G1 32 45.7 25 89.3 57 58.2
– G2 + G3 38 54.3 3 10.7 41 41.8
Depth of uterine stroma infiltration:
– up to 1/2 of thickness 42 60.0 18 64.3 60 61.2
– above 1/2 of thickness 28 40.0 10 35.7 38 38.8
Total 70 100.0 28 100.0 98 100.0
Table I. Characteristics of the analyzed group of patients
Population, histological and No. of treated 5-year NED survivals P value
clinical features patients No. of pts. %
Age:
– under 60 52 25 48.1 NS
– 60 and over 46 23 50.0
Microscopic type of sarcoma:
– LMS 70 27 38.6 < 0.01
– ESS 28 21 75.0
Differentiation grade:
– G1 57 28 49.1 NS
– G2 + G3 41 20 48.8
Depth of myometrial infiltration:
– up to 1/2 of thickness 60 30 50.0 < 0.01
– above 1/2 of thickness 38 18 47.4
Clinical stage of disease:
– I 58 37 63.8
– II 16 8 50.0 NS
– III 14 3 21.4
– IVA 10 0 0
Total 98 48 49.0
Table II. Relation between the treatment results and the population, histological and clinical features
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to recurrence, starting from the end of treatment,
was 13 months. In 43 patients, relapse of the
malignant process appeared up to 2 years
of follow-up. Sites of recurrences are presented in
Table IV.
The most common cause of treatment failure in
the analyzed group of patients with US was distant
metastases found in 36 (75%) uncured patients.
Loco-regional US relapse appeared in 18 (37.5%)
patients, and out of this number, in 12 (25%)
uncured patients it was the only cause of failure.
The metastases locations were: lungs (31 patients),
liver (4 patients) and brain (1 patient).
From among 6 uncured ESS patients, locoregional
relapse of sarcoma was observed in 5 (93.3%),
whereas among 41 LMS patients, this relapse was
found only in 12 (29.3%). This difference is statistically
significant (log-rank test p < 0.05). Thus, the uncured
ESS patients died with statistically significantly higher
frequency, due to loco-regional relapse of sarcoma,
than did the uncured LMS patients in whom
the basic cause of treatment failure was
generalization of the malignant process.
Discussion
The composition of the group in terms
of population, clinical and histological factors is
similar to the majority of US patient groups treated
with surgery followed by radiotherapy presented in
the literature [1, 3, 6].
The most common type of sarcoma was LMS, as
reported by other authors [1, 11, 13, 15]. The average
age of LMS patients was 63 years of age, and was
statistically significantly higher than the average age
of ESS patients, which is also in agreement with
data from the literature [3, 16]. The prognosis
of leiomyosarcoma depends chiefly upon the extent
of spread. Extrauterine disease is the most potent
predictor of survival [17]. For tumours confined to
the uterine corpus, some investigators have found
that size of neoplasm is an important prognostic
factor with the demarcation occurring at 5 cm [17].
A number of histological and immunohistochemical
features have been investigated as prognostic
factors in uterine LMS. Of these, the most important
is mitotic count, accessible to all pathologist [10, 17].
The prognostic significance of Ki67 antigen
expression, a widely used immunohistochemical
surrogate for counting mitotic figures, is far less
clear, as well as p53 overexpression and tumour
necrosis [14, 17].
Endometrial stromal sarcomas (ESS) have been
traditionally divided into low- and high-grade types
based on mitotic count. However, because
of the lack of specific differentiation and because
they bear no histological resemblance to
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Microscopic type of sarcoma
Total
LMS ESS
Grade No. of 5-year NED No. of 5-year NED No. of 5-year NED 
pts. survival pts. survival pts. survival
treated No. of % treated No. of % treated No. of %
pts. pts. pts.
I 42 22 52.4 16 15 93.8 58 37 63.8
II 10 4 40.0 6 4 66.7 16 8 50.0
III 11 1 9.1 3 2 66.7 14 3 21.4
IVA 7 0 0 3 0 v 10 0 21.4
Total 70 27 38.6 28 21 75.0 98 48 49.0
Table III. Relation between the treatment results, the microscopic type of sarcoma and grade
Causes of treatment Microscopic type of sarcoma
Total
failure LMS ESS
No. of  pts. % No. of  pts. % No. of  pts. %
Loco-regional recurrence 9 21.4 3 50.0 12 25
Loco-regional recurrence + 4 9.6 2 30.3 6 12.5
distant metastases
Distant metastases 29 69 1 16.7 30 62.5
Total 42 100.0 6 100.0 48 100.0
Table IV. Causes of failure in combined treatment of patients with uterine sarcoma
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endometrial stroma, it has been proposed that they
be designated undifferentiated endometrial or
uterine sarcoma. In the latest WHO classification [14]
the distinction between low grade ESS and
undifferentiated endometrial sarcoma is not made
on the basis of mitotic count but on features such
as nuclear pleomorphism and necrosis. Patients with
low-grade stromal sarcomas confined to the uterus
present a 5-year survival rate over 90%; however,
recurrences are not uncommon, ranging up to 25%
in stage I patients. Unfortunately, there are no
histopathological parameters to predict which
patients with tumour limited to the uterus are at
risk of recurrence. For the whole group of low-grade
stromal sarcomas the surgical stage is the best
predictor of recurrence and survival [16, 17].
Some authors suggest that division between
low-grade and high-grade stromal sarcomas (LGSS
and HGSS) should be based not only on histological
differentiation, but also on analysis of mitotic index,
vasculature pattern, nuclear pleomorphism and
necrosis [18, 19]. This division is not always clear
among some authors [20]. Because of the lack
of those data in the material only histological
differentiation (G) was studied. In the analyzed group,
from among 28 ESS patients, high-grade ESS (G2, G3)
was found only in 3 (10.7%), while the remaining
25 (89.3%) patients had low-grade ESS (G1).
The literature presents contrasting views as to
the value and significance of differentiation between
low-grade and high-grade ESS patients. Some authors
underscore significant differences in the clinical course
and prognosis of ESS patients, pointing to more
aggressive disease and inferior treatment results in
the case of high-grade ESS. Other authors, however,
question both the diagnostic criteria and prognostic
value of differentiation between the two types of ESS
[4]. One of our patients with high-grade ESS survived
for 5 years with no evidence of disease and
the remaining two died in the second year
of treatment due to sarcoma spread to the lungs.
The advancement of the malignant process is
similar to that reported in the literature. Clinical
stage I or II was found in 75.5% of patients, while
according to the literature, stage I or II is diagnosed
in 59-80% of patients [1, 14, 21, 22].
From among the 98 patients, 49% survived for
5 years with no evidence of disease. The obtained
percentage of cure is in agreement with the data from
the literature, which reported 5-year disease-free
survival rates of 20-57% in US patients. This wide
range of 5-year disease-free survival rates probably
results from the very diverse population and clinical
composition of the presented groups of patients
[1, 2, 7, 8, 12, 20]. Among stage I US patients, 63.8%
survived with no evidence of disease for 5 years,
among stage II patients 50.0%, stage III 21.4%, and
stage IVA 0%. These results are in concordance with
the data obtained from the literature, where
depending on US advancement stage, the respective
values are as follows: stage I 50-75% [1, 22],
stage II 40-50% [1, 3], stage III 8-16% [1, 3], and stage
IVA 0-10% [1].
In the analyzed group, among ESS patients,
5-year NED survival rate was 75%, while
the literature reports between 70 and 82% [1, 17, 23].
Among patients with LMS, 5-year NED survival was
observed in 38.6% of patients, whereas in
the literature this percentage ranges between 15
and 49% [1, 6]. Thus, the results obtained at
the Oncology Centre in Krakow are in agreement
with the data provided by other authors.
Summing up this part of the study, the combination
of surgery followed by postoperative radiotherapy
results in cure in around a half of the total number
of patients with US based on our own results and
the data from the literature. In early-stage cases
(stages I and II), 5-year disease-free survival is obtained
in over 60% of patients. Surgery combined with
postoperative radiotherapy is, however, ineffective in
treating US patients with stages III and IVA disease.
As already mentioned in the introduction, the role
of postoperative radiotherapy in patients with US
remains a subject of controversy [1, 2, 18, 19, 24]. In
this study, all patients received combined therapy
and there is no control group treated with surgery
alone. Therefore it is impossible to provide data that
would offer new insights in this debate.
The multivariate analysis of prognostic factors
we performed has shown that statistically significant
factors affecting the treatment results were:
the stage of the disease and the US microscopic
type.
In the analyzed group of early-stage US
(stages I and II) patients, 5-year NED survival rate
was 60.8%, while in advanced disease only 12.5%
(including US patients with stage IVA for whom
the survival percentage was 0). This dependence is
fully confirmed by all reports in the literature [1, 3, 6].
Also the presence of better results in combined
treatment of ESS patients, compared to LMS
patients (at comparable stages of advancement), is
extensively supported by the data from the literature
[1, 3, 19]. There are authors who emphasize
a particularly poor prognosis in patients with
high-grade ESS [24]. In our study group, from
among 3 such patients, 1 survived 5 years with no
evidence of disease. Some authors stress higher
radiosensitivity of ESS [3, 23] although there are also
different opinions on this subject [25]. The literature
reports a worse prognosis in the group of patients
with LMS and that this worse prognosis is
connected with early occurrence of distant
metastases in this type of sarcoma [3].
Some authors point to the prognostic significance
of such factors as age or grade [1, 19]. In our patients,
Uterine sarcomas – treatment and prognostic factors
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as well as in the uni- and multivariate analysis, no
statistically significant effect of those factors on
5-year NED survival of patients was observed.
The analysis of the literature shows that
the studies of other authors describe a number
of prognostic factors that we did not analyze.
These include: tumour size [24], DNA ploidy [6, 26],
mitotic index [26], presence of necrotic foci [27],
patients’ performance status and p53 protein
expression [28].
The basic cause of treatment failure in our study
population was distant metastases, found in
over 75% of patients not cured from US. In general,
the literature points out that the spread
of the malignant process to the lungs, liver, brain
and bones is most often the reason for failure in
patients with uterine sarcoma, particularly in
the LMS subgroup [1, 3, 28, 29]. It is slightly different
in ESS patients, where loco-regional recurrences are
more frequent [20, 29]. This fact was confirmed in
our study, in which out of 6 ESS patients not cured
from the malignant process, 5 patients (83.3%)
developed loco-regional relapses of sarcoma.
In view of the fact that the basic cause
of treatment failure in US (in particular in the LMS
group) is the spread of the malignant process,
further improvement of treatment results is desired
in combining surgery or surgery plus radiotherapy
with systemic chemotherapy treatment. Attempts
in refining treatment have not yielded
a breakthrough for patients with US [3, 23, 30-32].
There are items in the literature reporting
the effectiveness of hormonal treatment in ESS
patients, particularly those with low-grade ESS
[24, 33, 34]. These may offer patients and physicians
other treatment options.
In conclusion, combined surgical treatment
followed with radiotherapy was an effective
treatment method in patients with early (FIGO
stages I and II) uterine sarcoma, offering a chance
of curing over 60% of patients. This combination
was ineffective in the group of patients with locally
advanced (FIGO stages III and IVA) US, where only
single patients with stage III sarcoma were cured.
The basic cause of combined treatment failure in
LMS patients was the spread of the disease, and in
the ESS group, loco-regional relapse of the sarcoma.
Independent prognostic factors in patients
treated with surgery followed by postoperative
radiotherapy were advancement of disease and its
microscopic type.
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